Q4 2024 American Well Corp Earnings Call Transcript
Key Points
- American Well Corp (AMWL) achieved significant progress in its strategic initiatives, including the successful deployment of its solution across the Military Health System, marking the most significant growth initiative in the company's history.
- The company reported a substantial increase in subscription software revenue, which grew by over 30% compared to the previous quarter, driven by strategic client deployments.
- AMWL improved its adjusted EBITDA for the third consecutive quarter, reflecting effective cost reduction measures and a focus on high-margin revenue growth.
- The divestiture of Amwell Psychiatric Care strengthened the company's balance sheet by adding up to $30 million in cash, allowing AMWL to focus on its core platform.
- The company has a strong cash position with $228 million in cash and marketable securities and zero debt, providing financial stability and flexibility for future growth initiatives.
- Total revenue for Q4 2024 was flat compared to Q4 2023, indicating a lack of overall revenue growth despite strategic initiatives.
- The number of completed visits in Q4 decreased by approximately 18% year-over-year, reflecting market-wide and client execution-related challenges.
- AMWL's adjusted EBITDA remained negative at $22.8 million for the quarter, although it showed improvement from the previous year.
- The company experienced significant churn in 2024, which impacted its revenue and required managed attrition of clients not aligned with its strategic direction.
- There is a dependency on the successful renewal and expansion of government contracts, such as the DHA, which could impact future revenue growth if not secured.
Thank you for standing by, and welcome to Amwell's fourth-quarter 2024 earnings conference call. (Operator Instructions)
I would now like to hand the call over to Sue Dooley, Head of Investor Relations. Please go ahead.
Hello, everyone. Welcome to Amwell's conference call to discuss our fourth fiscal quarter of 2024. This is Sue Dooley of Amwell Investor Relations. Joining me today are: Amwell's Chairman and CEO, Dr. Ido Schoenberg; and Mark Hirschhorn, our CFO and Chief Operating Officer.
Earlier today, we distributed a press release detailing our announcement. Our earnings report is posted on our website at investors.amwell.com and is also available through normal news sources. This conference call is being webcast live on the IR page of our website, where a replay will be archived.
Before we begin our prepared remarks, I'd like to take this opportunity to remind you that during the call, we will make forward-looking statements regarding projected operating results and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
